A AMYLYX PHARMACEUTICALS INC
| Market Cap | $1.50B |
| P/E Ratio | — |
| Forward P/E | -10.92 |
| Dividend Yield | — |
| Beta | -0.30 |
| 52W Range | $3.11 - $17.49 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 25 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Klee Justin B.Co-Chief Executive Officer | Sale | 29,282 | $14.47 | $423.76K | 02 Mar 2026 | 04 Mar 2026 |
| FRATES JAMES MChief Financial Officer | Sale | 7,909 | $14.52 | $114.85K | 02 Mar 2026 | 04 Mar 2026 |
| Bedrosian Camille LChief Medical Officer | Sale | 6,461 | $14.58 | $94.21K | 02 Mar 2026 | 04 Mar 2026 |
| Cohen Joshua BCo-Chief Executive Officer | Sale | 29,282 | $14.48 | $424.12K | 02 Mar 2026 | 04 Mar 2026 |
| Mazzariello GinaChief Legal Officer | Sale | 6,844 | $14.52 | $99.38K | 02 Mar 2026 | 04 Mar 2026 |
| Gina MazzarielloChief Legal Officer | Sale | 3,419 | $14.14 | $48.35K | 23 Feb 2026 | 25 Feb 2026 |
| Mazzariello GinaChief Legal Officer | Sale | 3,419 | $14.14 | $48.35K | 23 Feb 2026 | 25 Feb 2026 |
| Mazzariello GinaChief Legal Officer | Sale | 3,448 | $14.65 | $50.52K | 02 Feb 2026 | 04 Feb 2026 |
| Cohen Joshua BCo-Chief Executive Officer | Sale | 15,500 | $14.68 | $227.59K | 02 Feb 2026 | 04 Feb 2026 |
| FRATES JAMES MChief Financial Officer | Sale | 3,557 | $14.65 | $52.10K | 02 Feb 2026 | 04 Feb 2026 |
| Klee Justin B.Co-Chief Executive Officer | Sale | 15,500 | $14.69 | $227.62K | 02 Feb 2026 | 04 Feb 2026 |
| James M FratesChief Financial Officer | Sale | 3,557 | $14.65 | $52.10K | 02 Feb 2026 | 04 Feb 2026 |
| Joshua B CohenCo-Chief Executive Officer | Sale | 15,500 | $14.68 | $227.59K | 02 Feb 2026 | 04 Feb 2026 |
| Gina MazzarielloChief Legal Officer | Sale | 3,448 | $14.65 | $50.52K | 02 Feb 2026 | 04 Feb 2026 |
| Justin B. KleeCo-Chief Executive Officer | Sale | 15,500 | $14.69 | $227.62K | 02 Feb 2026 | 04 Feb 2026 |
| Klee Justin B.Co-Chief Executive Officer | Sale | 1,995 | $13.89 | $27.70K | 16 Jan 2026 | 20 Jan 2026 |
| Cohen Joshua BCo-Chief Executive Officer | Sale | 1,974 | $13.83 | $27.30K | 16 Jan 2026 | 20 Jan 2026 |
| Cohen Joshua BCo-Chief Executive Officer | Sale | 136,193 | $13.59 | $1.85M | 15 Jan 2026 | 20 Jan 2026 |
| Klee Justin B.Co-Chief Executive Officer | Sale | 136,193 | $13.58 | $1.85M | 15 Jan 2026 | 20 Jan 2026 |
| Cohen Joshua BCo-Chief Executive Officer | Sale | 7,715 | $11.09 | $85.60K | 06 Jan 2026 | 08 Jan 2026 |
| Klee Justin B.Co-Chief Executive Officer | Sale | 7,715 | $11.09 | $85.59K | 06 Jan 2026 | 08 Jan 2026 |
| FRATES JAMES MChief Financial Officer | Sale | 3,326 | $11.11 | $36.95K | 06 Jan 2026 | 08 Jan 2026 |
| Firestone Karen | Buy | 8,100 | $12.45 | $100.84K | 23 Dec 2025 | 23 Dec 2025 |
| Bedrosian Camille LChief Medical Officer | Sale | 6,580 | $14.35 | $94.42K | 01 Dec 2025 | 03 Dec 2025 |
| Camille L BedrosianChief Medical Officer | Sale | 6,580 | $14.35 | $94.42K | 01 Dec 2025 | 03 Dec 2025 |
Frequently Asked Questions
What is AMLX stock price today?
AMYLYX PHARMACEUTICALS INC (AMLX) is currently trading at $13.70. The stock has a 52-week range of $3.11 to $17.49 and a market capitalization of $1.50B.
Is AMLX a good stock to buy in 2026?
AMYLYX PHARMACEUTICALS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +292.0%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling AMLX stock?
There have been 25 insider transactions for AMLX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has AMLX stock performed over the past year?
AMYLYX PHARMACEUTICALS INC (AMLX) has returned +292.0% over the past 12 months. The stock traded between $3.11 and $17.49 during this period, and is currently at $13.70.
Which hedge funds own AMLX (AMYLYX PHARMACEUTICALS INC)?
0 tracked hedge funds currently hold AMLX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is AMLX's market cap and valuation?
AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of $1.50B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is AMLX's revenue and profitability?
AMYLYX PHARMACEUTICALS INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of N/A.
What sector is AMLX in and who are its biggest institutional holders?
AMYLYX PHARMACEUTICALS INC (AMLX) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.